ProCE Banner Activity

PADMA: ET + Palbociclib vs Standard Chemotherapy in High-Risk HR+/HER2- MBC

Conference Coverage
Slideset

In the phase IV PADMA trial, first-line endocrine therapy (ET) plus palbociclib vs single-agent chemotherapy with or without ET maintenance led to clinically meaningful and statistically significant improvement in time to treatment failure in patients with HR+/HER2- MBC and an indication for treatment with chemotherapy.

Released: December 17, 2024

Expiration: June 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation